Inversion Crackdown: Does It Spell The End For Pfizer/AstraZeneca?

The U.S. Treasury’s initiative to reduce M&A motivated by tax avoidance could leave Pfizer in a lurch, without an attractive acquisition target to reenergize the big pharma’s long-term outlook.